Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17554382rdf:typepubmed:Citationlld:pubmed
pubmed-article:17554382lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0018956lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0079744lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C1096776lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:17554382lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:17554382pubmed:issue8lld:pubmed
pubmed-article:17554382pubmed:dateCreated2007-7-19lld:pubmed
pubmed-article:17554382pubmed:abstractTextA prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged <65 years (74 score 2, 38 score 3) entered the study protocol. There were five early and two late toxic deaths. Overall 90 patients (80%) reached clinical remission (CR); at a median 48 months follow-up, 87 (78%) patients are alive, 82 (73%) in continuous CR, with 4 year overall survival (OS) and event-free survival (EFS) projections of 76% (CI 68-85%) and 73% (CI 64-81%), respectively. There were no significant differences in OS and EFS between subgroups with Germinal-Center and Activated B-cell phenotype. Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.lld:pubmed
pubmed-article:17554382pubmed:languageenglld:pubmed
pubmed-article:17554382pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:citationSubsetIMlld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17554382pubmed:statusMEDLINElld:pubmed
pubmed-article:17554382pubmed:monthAuglld:pubmed
pubmed-article:17554382pubmed:issn0887-6924lld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:GallaminiAAlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:BoccadoroMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:MajolinoIIlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:StellaMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:GianniA MAMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:TarellaCClld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:FornariAAlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:MagniMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:CorradiniPPlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:BregniMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:Di NicolaMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:CaraccioloDDlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:MirtlLLlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:RemottiDDlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:CabrasAAlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:ZanniMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:PonzoniMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:DevizziLLlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:CominoAAlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:NoveroDDlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:PattiCClld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:RosatiTTlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:ZoliVVlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:CalviRRlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:PescarolloAAlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:LadettoMMlld:pubmed
pubmed-article:17554382pubmed:authorpubmed-author:Gruppo...lld:pubmed
pubmed-article:17554382pubmed:issnTypePrintlld:pubmed
pubmed-article:17554382pubmed:volume21lld:pubmed
pubmed-article:17554382pubmed:ownerNLMlld:pubmed
pubmed-article:17554382pubmed:authorsCompleteYlld:pubmed
pubmed-article:17554382pubmed:pagination1802-11lld:pubmed
pubmed-article:17554382pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:meshHeadingpubmed-meshheading:17554382...lld:pubmed
pubmed-article:17554382pubmed:year2007lld:pubmed
pubmed-article:17554382pubmed:articleTitleProlonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).lld:pubmed
pubmed-article:17554382pubmed:affiliationDip Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy. corrado.tarella@unito.itlld:pubmed
pubmed-article:17554382pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17554382pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17554382lld:pubmed